CAMPATH-1H monoclonal antibody in therapy for previously treated low- grade non-Hodgkin's lymphomas: A phase II multicenter study

Journal of Clinical Oncology

Volumn 16, Issue 10, 1998, Pages 3257-3263

  Lundin, J ^a   Osterborg, A ^a   Brittinger, G ^a   Crowther, D ^a   Dombret, H ^a   Engert, A ^a   Epenetos, A ^a   Gisselbrecht, C ^a   Huhn, D ^a   Jaeger, U ^a   Thomas, J ^a   Marcus, R ^a   Nissen, N ^a   Poynton, C ^a   Rankin, E ^a   Stahel, R ^a   Uppenkamp, M ^a   Willemze, R ^a   Mellstedt, H ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; T CELL LYMPHOMA; TREATMENT OUTCOME;

EID: 0031757274     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.10.3257     Document Type: Article

References (23)

1. Portlock C, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979
2. Young RC, Longo DK, Glatstein E, et al: The treatment of indolent lymphomas: Watchful waiting vs aggressive combined modality treatment. Semin Hematol 25:11-16, 1988 (suppl 2)
3. Ideström K, Kimby E, Björkholm M, et al: Treatment of chronic lymphocytic leukemia and well-differentiated lymphocytic lymphoma with continuous low- or intermittent high-dose prednimustine versus chlorambucil/prednisolone. Eur J Cancer Clin Oncol 18:1117-1123, 1982
4. Riechmann L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988
5. Dyer MJS, Hale G, Marcus R, et al: Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1H monoclonal antibodies. Leuk Lymph 2:179-193, 1990
6. W52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 47:313-317, 1994
7. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1:1394-1399, 1988
8. Lim SH, Davey G, Marcus R: Differential response in a patient treated with CAMPATH-1H monoclonal antibody for refractory non-Hodgkin lymphoma. Lancet 341:432-433, 1993
9. Hale G, Clark M, Waldmann H: Therapeutic potential of rat monoclonal antibodies. Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 134:3056-3061, 1985
10. Xia MQ, Hale G, Waldmann H: Efficient complement-mediated lysis of cells containing the CAMPATH-1H (CDw52) antigen. Mol Immunol 30:1089-1096, 1993
11. Maloney DG, Smith B, Appelbaum FR: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL). Blood 88:637a, 1996 (suppl 1, abstr)
12. + and CD52-T cells are induced in responding B cell lymphoma patients treated with CAMPATH-1H (anti-CD52). Eur J Haematol 58:5-13, 1997
13. Fagerberg J, Hjelm A-L, Ragnhammar P, et al: Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes. Cancer Res 55:1824-1827, 1995
14. de Kroon J, de Paus R, Kluin-Nelemans H, et al: Anti-CD45 and anti-CD52 (CAMPATH) monoclonal antibodies effectively eliminate systemically disseminated human non-Hodgkin's lymphoma B cells in SCID mice. Exp Hematol 24:919-926, 1996
15. Osterborg A, Fassas A, Anagnostopoulos A, et al: Humanized CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. BrJ Haematol 93:151-153, 1996
16. Österborg A, Dyer MJS, Bunjes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 15:1567-1574, 1997
17. Bowen AL, Zomas A, Emmett E, et al: Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617-619, 1997
18. Pawson R, Dyer MJS, Barge R, et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15:2667-2672, 1997
19. Isaacs JD, Watts RA, Hazleman BL, et al: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748-752, 1992
20. Rai KR, Hoffman M, Janson D, et al: Immunosuppression and opportunistic infections (OI) in patients with chronic lymphocytic leukemia (CLL) following CAMPATH-1H therapy. Blood 86:348a, 1995 (suppl 1, abstr)
21. DelleKarth G, Laczika K, Scholten C, et al: Clearance of PCR-detectable lymphoma cells from the peripheral blood, but not bone marrow, after therapy with CAMPATH-1H. Am J Hematol 50:146-147, 1995
22. Dyer MJS, Kelsey SM, Mackay HJ, et al: In vivo "purging" of residual disease in CLL with Campath-1H. Br J Haematol 97:669-672, 1997
23. Gilleece MH, Dexter TM: Effect of CAMPATH-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807-812, 1993